GENB · Generate Biomedicines, Inc. · Proposed Sales
$13.06
+0.49 (+3.90%)
At close · Nov 6
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“As of December 31, 2025, the Company had concluded that there was substantial doubt about its ability to continue as a going concern. Upon closing of the IPO and receipt of the associated cash proceeds, the Company has alleviated the substantial doubt that previously existed, and based on the Company’s current capital resources, which consists of its cash, cash equivalents and marketable securities on hand at June 30, 2026, it expects to have sufficient cash to fund our current operating plan into the first half of 2028.”View the 10-Q filed Aug 6, 2026
Market Cap
$1.68B
Shares
128.35M
Volume · Nov 6
632.2K
Avg daily vol (3M)
1.2M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2026-10-29 | ARNOLD FRANCES | Director | 11,409 | 2026-10-29 | Fidelity Brokerage Services LLC |
| 2026-09-02 | ARNOLD FRANCES | Director | 32,210 | 2026-09-02 | Fidelity Brokerage Services LLC |
| 2026-09-01 | ARNOLD FRANCES | Director | 1,000 | 2026-09-01 | Fidelity Brokerage Services LLC |
Showing 1–3 of 3 filings
Key facts
CIK
2100782
CUSIP
370920100
13F (30d)
35 filings
35 filers
Visit website
Investor relations